-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
February 2019
-
Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer
By Michael MacManus, MD, FRANZCR, and Tim Akhurst, MD, FRACP Posted: March 1, 2019 Dr. Michael MacManus 18F-FDG PET/CT scans portray living biology and are indispensable in thoracic oncologic evaluations, including presurgical staging of NSCLC, patient selection and target-volume definition in curativeintent radiation therapy (RT), and the evaluation of patients with suspected recurrence after definitive…
-
Lung Cancer Pathology Pioneer Dr. Adi Gazdar Dies at 81
Posted: March 1, 2019 Adi Gazdar, MD, a true giant in the field of lung cancer research, passed away on December 29, 2018. Dr. Gazdar was the W. Ray Wallace Distinguished Chair in Molecular Pathology Research and professor of pathology at the Hamon Center for Therapeutic Oncology Research and pathology at UT Southwestern Medical Center.…
-
Uncommon Oncogenic Drivers in NSCLC
By Karen L. Reckamp, MD, MS Posted: March 1, 2019 Dr. Karen L. Reckamp Identification of genetic alterations in NSCLC has transformed diagnosis and treatment for patients with advanced disease. Identification of activating mutations in the EGFR gene in 2004 started the shift in our understanding of the complex biology of molecular subtypes of lung…
-
The Changing the Landscape of Tobacco Products: Potential Effects of ENDS and HTPs
By Carolyn M. Dresler, MD, MPA Posted: March 1, 2019 It is common knowledge that the number one cause of preventable deaths in the world is from tobacco use—overwhelmingly from cigarettes.1 Most of the deaths from tobacco use, particularly from smoking, are from cardiovascular disease, followed by cancer, and then chronic obstructive pulmonary disease (COPD).2…
-
Diagnostic Oncology: Reports from the IASLC Pathology Committee
By Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE Posted: March 1, 2019 There was a time, remembered by us older pathologists, when the image of pathology was that of a rather peripheral specialty, sometimes perceived to have limited clinical relevance, delivered by physicians who were never seen, rarely heard, and were usually banished to some…
-
Improving Clinical Trials Through Clinician, Patient Use of Social Media
By DR CamidgePosted: March 1, 2019 The National Cancer Institute featured a workshop in June 2018 titled “At the Crossroads of Social Media and Clinical Trials: A Workshop on the Future of Clinician, Patient, and Community Engagement.” The two-day conference brought together key stakeholders in this area including clinical trialists, internet researchers, patient navigators, advocates,…
-
Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC
Posted: March 1, 2019 In the following interview, Jamie E. Chaft, MD, a medical oncologist at the Memorial Sloan Kettering Cancer Center, discusses new data on induction immunotherapy for patients with resectable NSCLC as well as the recently published summary paper on the IASLC–U.S. Food and Drug Administration (FDA) summit on neoadjuvant therapies.1 Q: What…
-
IMpower133: Finally Moving the Needle in SCLC
By Stephen V. Liu, MD Posted: March 1, 2019 Dr. Stephen V. Liu The addition of atezolizumab to standard chemotherapy for extensive-stage SCLC achieved what, for decades, had been beyond reach: an improvement in survival in this disease. Since the 1980s, our standard of care for SCLC has been a platinum chemotherapy agent plus etoposide.…
-
The Rising Cost of Lung Cancer Therapies: What Are the Global Implications?
By Doreen A. Ezeife, MD, FRCPC; Malcolm Ryan; and Natasha B. Leighl, MD, MMSc, FRCPC, FASCO Posted: March 1, 2019 Dramatic improvements in lung cancer outcomes can be attributed to recent advances in novel targeted therapy and immunotherapy. As the treatment paradigm for lung cancer evolves, concerns about the rising cost of these novel therapeutics…
-
An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old Strategies
Posted: March 1, 2019 Federico Cappuzzo, MD, PhD, has been the director of Medical Oncology at AUSL della Romagna, Ravenna, Italy, since April 2016; in January 2017 he became the director of the Hematology and Oncology Department. The author of more than 200 papers, Dr. Cappuzzo is an extremely active member of the IASLC, having…
View ILCN Archives
Provider Resources
Popular Articles